Dermata Therapeutics, Inc. (DRMA) compared with its closest peers (APUS, BOLT, ACXP, ENVB, PCSA). Peer set by Business model: Biotech (Clinical / Commercial-Stage); 10 closest by market cap; US-domiciled. First-party data.
| Company | Market Cap | P/E |
|---|---|---|
| Apimeds Pharmaceuticals US, Inc (APUS) | $7.74M | -2.9 |
| Bolt Biotherapeutics, Inc. (BOLT) | $7.19M | -0.3 |
| Acurx Pharmaceuticals, Inc. (ACXP) | $6.36M | -0.5 |
| Enveric Biosciences, Inc. (ENVB) | $6.36M | -0.1 |
| Processa Pharmaceuticals, Inc. (PCSA) | $5.67M | -0.3 |
| Cadrenal Therapeutics, Inc. Common Stock (CVKD) | $5.60M | -1.0 |
| Pulmatrix, Inc. (PULM) | $5.42M | -1.6 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | $5.30M | — |
| AEON Biopharma, Inc. (AEON) | $5.12M | -0.3 |
| Aptevo Therapeutics Inc. (APVO) | $4.81M | -0.1 |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
DRMA overview · DRMA earnings · DRMA financials · DRMA KPIs · DRMA investor relations · DRMA ownership · DRMA filings
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.